Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nova Eye Medical ( (AU:EYE) ) has shared an announcement.
Nova Eye Medical reported record global sales of US$6.1 million for the December 2025 quarter, up 38% year-on-year and 25% on the previous quarter, driving six‑month revenue to US$10.9 million, a 29% increase on the prior corresponding period. For the twelve months to 31 December 2025, group revenue reached about US$21 million, up 24% and roughly three times the estimated industry growth rate, underpinned by sustained strength in the US market—where iTrack Advance has delivered six consecutive halves of sales growth at an annualised rate of about 40%—and robust gains in Rest of World markets, while China lagged ahead of expected 2026 sales of iTrack Advance following its recent approval. These results, which are subject to audit, highlight Nova Eye’s accelerating market penetration in minimally invasive glaucoma surgery and reinforce its competitive positioning within the sector.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical Limited is an ophthalmic medical device company listed on the ASX that focuses on glaucoma treatment technologies. Its primary product platform is the iTrack family of minimally invasive devices used in canal-based glaucoma surgery, with a growing commercial footprint led by the United States and supported by markets in Europe, China and the broader Rest of World segment.
YTD Price Performance: 17.42%
Average Trading Volume: 251,563
Technical Sentiment Signal: Hold
Current Market Cap: A$44.15M
See more insights into EYE stock on TipRanks’ Stock Analysis page.